New high-throughput, no-wash assays contribute to the development, manufacture and quality control of safer, more effective biotherapeutics
Lupin is committed to providing new affordable treatment options to healthcare providers and patients
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
The two-day event will showcase achievements and address issues pertaining to the industry
Sanofi’s DE&I Board will include three of the most influential voices in the DE&I space as Board members appointed for 3 years: organizational psychologist & best-selling author John Amaechi, award-winning social entrepreneur Caroline Casey, and DE&I pioneer and renowned thought-leader Dr. Rohini Anand
CanSinoBIO will continue to focus on developing a variety of innovative preventive vaccines in its diversified product pipeline with proprietary technologies, including the inhaled version of its COVID-19 vaccine, Convidecia
It also secures US $ 10 million for US launch and commercialization
The symposium was organized by the Gut Microbiota and Probiotic Science Foundation (India) and Medanta Institute of Education and Research, Gurugram, and Amity University, Gurugram
Supply increase to help meet growing global demand
Intas has developed a biosimilar of Lucentis, which is currently under Phase III global trial for submission in major countries including EMA & the US
Subscribe To Our Newsletter & Stay Updated
